Multidrug chemotherapy using bleomycin, methotrexate, and cisplatin combined with radical radiotherapy in advanced head and neck cancer

J. Zidan, A. Kuten, Y. Cohen, E. Robinson

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Thirty‐one patients with Stage III‐IV head and neck squamous cell cancer were treated by three courses of combination chemotherapy using bleomycin, methotrexate, and cisplatin followed by a radical course of radiation and in two cases by surgery. Of 29 evaluable patients, 4 (14%) achieved complete remission (CR) with chemotherapy and 13 (45%) had a partial response (PR). With the addition of radiotherapy and surgery, the CR rate increased to 72%. At 30 months the actuarial survival of all evaluable patients was 61% and of complete responders, 76%. Patients with nasopharyngeal cancer had an actuarial survival of 80% at 30 months, whereas patients with squamous malignancies at other sites in the head and neck region had an actuarial survival of only 37%. Side effects were tolerable. It is concluded that complete responders to combination chemotherapy and radiotherapy have a survival benefit at 30 months. The combined approach is most effective in nasopharyngeal cancer. Cancer 59:24–26, 1987.

Original languageEnglish
Pages (from-to)24-26
Number of pages3
JournalCancer
Volume59
Issue number1
DOIs
StatePublished - 1 Jan 1987
Externally publishedYes

Fingerprint

Dive into the research topics of 'Multidrug chemotherapy using bleomycin, methotrexate, and cisplatin combined with radical radiotherapy in advanced head and neck cancer'. Together they form a unique fingerprint.

Cite this